A phase 3, parallel group, randomized, double-blind, double-dummy, placebo and active-controlled multicenter trial to investigate the efficacy, tolerability and safety of fesoterodine sustained release in subjects with overactive bladder syndrome

Trial Profile

A phase 3, parallel group, randomized, double-blind, double-dummy, placebo and active-controlled multicenter trial to investigate the efficacy, tolerability and safety of fesoterodine sustained release in subjects with overactive bladder syndrome

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Nov 2014

At a glance

  • Drugs Fesoterodine (Primary) ; Tolterodine
  • Indications Overactive bladder
  • Focus Therapeutic Use
  • Sponsors Pfizer; UCB
  • Most Recent Events

    • 01 Aug 2012 New source identified and integrated (German Clinical Trials Register, DRKS00004018).
    • 01 Aug 2012 New source identified and integrated (German Clinical Trials Register, DRKS00004018).
    • 09 Apr 2008 Pfizer has replaced UCB Pharma as a trial sponsor, according to ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top